SEARCH

SEARCH BY CITATION

References

  • Abad C, Martinez C, Juarranz MG, Arranz A, Leceta J, Delgado M et al. (2003). Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 124: 961971.
  • Abad C, Tan YV, Lopez R, Nobuta H, Dong H, Phan P et al. (2010). Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 107: 1955519560.
  • Adamou JE, Aiyar N, Van Horn S, Elshourbagy NA (1995). Cloning and functional characterization of the human vasoactive intestinal peptide (VIP)-2 receptor. Biochem Biophys Res Commun 209: 385392.
  • Alexander SPH, Mathie A, Peters JA (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1S324.
  • Arimura A, Shioda S (1995). Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: neuroendocrine and endocrine interaction. Front Neuroendocrinol 16: 5388.
  • Asnicar MA, Koster A, Heiman ML, Tinsley F, Smith DP, Galbreath E et al. (2002). Vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating peptide receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate. Endocrinology 143: 39944006.
  • Aton SJ, Colwell CS, Harmar AJ, Waschek J, Herzog ED (2005). Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons. Nat Neurosci 8: 476483.
  • Aubert N, Vaudry D, Falluel-Morel A, Desfeux A, Fisch C, Ancian P et al. (2008). PACAP prevents toxicity induced by cisplatin in rat and primate neurons but not in proliferating ovary cells: involvement of the mitochondrial apoptotic pathway. Neurobiol Dis 32: 6680.
  • Barwell J, Gingell JJ, Watkins HA, Archbold JK, Poyner DR, Hay DL (2012). Calcitonin and calcitonin receptor-like receptors: common themes with family B GPCRs? Br J Pharmacol 166: 5165.
  • Basille M, Gonzalez BJ, Leroux P, Jeandel L, Fournier A, Vaudry H (1993). Localization and characterization of PACAP receptors in the rat cerebellum during development: evidence for a stimulatory effect of PACAP on immature cerebellar granule cells. Neuroscience 57: 329338.
  • Basille M, Gonzalez BJ, Fournier A, Vaudry H (1994). Ontogeny of pituitary adenylate cyclase-activating polypeptide (PACAP) receptors in the rat cerebellum: a quantitative autoradiographic study. Brain Res Dev Brain Res 82: 8189.
  • Basille M, Vaudry D, Coulouarn Y, Jegou S, Lihrmann I, Fournier A et al. (2000). Comparative distribution of pituitary adenylate cyclase-activating polypeptide (PACAP) binding sites and PACAP receptor mRNAs in the rat brain during development. J Comp Neurol 425: 495509.
  • Bechtold DA, Brown TM, Luckman SM, Piggins HD (2008). Metabolic rhythm abnormalities in mice lacking VIP-VPAC2 signaling. Am J Physiol Regul Integr Comp Physiol 294: R344R351.
  • Beebe X, Darczak D, Davis-Taber RA, Uchic ME, Scott VE, Jarvis MF et al. (2008). Discovery and SAR of hydrazide antagonists of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor type 1 (PAC1-R). Bioorg Med Chem Lett 18: 21622166.
  • Besson J, Sarrieau A, Vial M, Marie JC, Rosselin G, Rostene W (1986). Characterization and autoradiographic distribution of vasoactive intestinal peptide binding sites in the rat central nervous system. Brain Res 398: 329336.
  • Bourgault S, Vaudry D, Segalas-Milazzo I, Guilhaudis L, Couvineau A, Laburthe M et al. (2009). Molecular and conformational determinants of pituitary adenylate cyclase-activating polypeptide (PACAP) for activation of the PAC1 receptor. J Med Chem 52: 33083316.
  • Breault L, Yon L, Montero M, Chouinard L, Contesse V, Delarue C et al. (2000). Occurrence and effect of PACAP in the human fetal adrenal gland. Ann N Y Acad Sci 921: 429433.
  • Brenneman DE, Eiden LE (1986). Vasoactive intestinal peptide and electrical activity influence neuronal survival. Proc Natl Acad Sci U S A 83: 11591162.
  • Cavallaro S, Copani A, D'Agata V, Musco S, Petralia S, Ventra C et al. (1996). Pituitary adenylate cyclase activating polypeptide prevents apoptosis in cultured cerebellar granule neurons. Mol Pharmacol 50: 6066.
  • Cheung CY, Holzwarth MA (1986). Fetal adrenal VIP: distribution and effect on medullary catecholamine secretion. Peptides 7: 413418.
  • Christopoulos A, Christopoulos G, Morfis M, Udawela M, Laburthe M, Couvineau A et al. (2003). Novel receptor partners and function of receptor activity-modifying proteins. J Biol Chem 278: 32933297.
  • Chu A, Caldwell JS, Chen YA (2010). Identification and characterization of a small molecule antagonist of human VPAC(2) receptor. Mol Pharmacol 77: 95101.
  • Colwell CS, Michel S, Itri J, Rodriguez W, Tam J, Lelievre V et al. (2003). Disrupted circadian rhythms in VIP- and PHI-deficient mice. Am J Physiol Regul Integr Comp Physiol 285: R939R949.
  • Colwell CS, Michel S, Itri J, Rodriguez W, Tam J, Lelievre V et al. (2004). Selective deficits in the circadian light response in mice lacking PACAP. Am J Physiol Regul Integr Comp Physiol 287: R1194R1201.
  • Couvineau A, Laburthe M (2012a). VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins. Br J Pharmacol 166: 4250.
  • Couvineau A, Laburthe M (2012b). The family B1 GPCR: structural aspects and interaction with accessory proteins. Curr Drug Targets 13: 103115.
  • Cutler DJ, Haraura M, Reed HE, Shen S, Sheward WJ, Morrison CF et al. (2003). The mouse VPAC2 receptor confers suprachiasmatic nuclei cellular rhythmicity and responsiveness to vasoactive intestinal polypeptide in vitro. Eur J Neurosci 17: 197204.
  • Daniel PB, Kieffer TJ, Leech CA, Habener JF (2001). Novel alternatively spliced exon in the extracellular ligand-binding domain of the pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 receptor (PAC1R) selectively increases ligand affinity and alters signal transduction coupling during spermatogenesis. J Biol Chem 276: 1293812944.
  • Dautzenberg FM, Mevenkamp G, Wille S, Hauger RL (1999). N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants. J Neuroendocrinol 11: 941949.
  • Dejda A, Bourgault S, Doan ND, Letourneau M, Couvineau A, Vaudry H et al. (2011). Identification by photoaffinity labeling of the extracellular N-terminal domain of PAC1 receptor as the major binding site for PACAP. Biochimie 93: 669677.
  • Delgado M, Martinez C, Johnson MC, Gomariz RP, Ganea D (1996). Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J Neuroimmunol 68: 2738.
  • Dickinson T, Fleetwood-Walker SM, Mitchell R, Lutz EM (1997). Evidence for roles of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) receptors in modulating the responses of rat dorsal horn neurons to sensory inputs. Neuropeptides 31: 175185.
  • Dickson L, Finlayson K (2009). VPAC and PAC receptors: from ligands to function. Pharmacol Ther 121: 294316.
  • Dickson L, Aramori I, McCulloch J, Sharkey J, Finlayson K (2006). A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology. Neuropharmacology 51: 10861098.
  • Edwards AV, Jones CT (1994). Adrenal responses to the peptide PACAP in conscious functionally hypophysectomized calves. Am J Physiol 266: E870E876.
  • Fabricius D, Karacay B, Shutt D, Leverich W, Schafer B, Takle E et al. (2011). Characterization of intestinal and pancreatic dysfunction in VPAC1-null mutant mouse. Pancreas 40: 861871.
  • Fahrenkrug J (1993). Transmitter role of vasoactive intestinal peptide. Pharmacol Toxicol 72: 354363.
  • Furness SGB, Wootten D, Christopoulos A, Sexton PM (2012). Consequences of splice variation on Secretin family G protein-coupled receptor function. Br J Pharmacol 166: 98109.
  • Ghatei MA, Takahashi K, Suzuki Y, Gardiner J, Jones PM, Bloom SR (1993). Distribution, molecular characterization of pituitary adenylate cyclase-activating polypeptide and its precursor encoding messenger RNA in human and rat tissues. J Endocrinol 136: 159166.
  • Goetzl EJ, Voice JK, Shen S, Dorsam G, Kong Y, West KM et al. (2001). Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC2 receptor for vasoactive intestinal peptide. Proc Natl Acad Sci U S A 98: 1385413859.
  • Gonzalez BJ, Basille M, Vaudry D, Fournier A, Vaudry H (1997). Pituitary adenylate cyclase-activating polypeptide promotes cell survival and neurite outgrowth in rat cerebellar neuroblasts. Neuroscience 78: 419430.
  • Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Martin J, Pozo D, Ganea D et al. (2006). Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses. Am J Pathol 168: 11791188.
  • Gourlet P, De Neef P, Cnudde J, Waelbroeck M, Robberecht P (1997a). In vitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptides 18: 15551560.
  • Gourlet P, Vandermeers A, Vertongen P, Rathe J, De Neef P, Cnudde J et al. (1997b). Development of high affinity selective VIP1 receptor agonists. Peptides 18: 15391545.
  • Gourlet P, Vertongen P, Vandermeers A, Vandermeers-Piret MC, Rathe J, De Neef P et al. (1997c). The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass. Peptides 18: 403408.
  • Gozes I (2011). NAP (davunetide) provides functional and structural neuroprotection. Curr Pharm Des 17: 10401044.
  • Gozes I, Brenneman DE (1989). VIP: molecular biology and neurobiological function. Mol Neurobiol 3: 201236.
  • Grace CR, Perrin MH, DiGruccio MR, Miller CL, Rivier JE, Vale WW et al. (2004). NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. Proc Natl Acad Sci U S A 101: 1283612841.
  • Gressens P, Marret S, Hill JM, Brenneman DE, Gozes I, Fridkin M et al. (1997). Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. J Clin Invest 100: 390397.
  • Gressens P, Besse L, Robberecht P, Gozes I, Fridkin M, Evrard P (1999). Neuroprotection of the developing brain by systemic administration of vasoactive intestinal peptide derivatives. J Pharmacol Exp Ther 288: 12071213.
  • Hamelink C, Tjurmina O, Damadzic R, Young WS, Weihe E, Lee HW et al. (2002). Pituitary adenylate cyclase-activating polypeptide is a sympathoadrenal neurotransmitter involved in catecholamine regulation and glucohomeostasis. Proc Natl Acad Sci U S A 99: 461466.
  • Hammack SE, Roman CW, Lezak KR, Kocho-Shellenberg M, Grimmig B, Falls WA et al. (2010). Roles for pituitary adenylate cyclase-activating peptide (PACAP) expression and signaling in the bed nucleus of the stria terminalis (BNST) in mediating the behavioral consequences of chronic stress. J Mol Neurosci 42: 327340.
  • Hannibal J, Jamen F, Nielsen HS, Journot L, Brabet P, Fahrenkrug J (2001). Dissociation between light-induced phase shift of the circadian rhythm and clock gene expression in mice lacking the pituitary adenylate cyclase activating polypeptide type 1 receptor. J Neurosci 21: 48834890.
  • Hannibal J, Brabet P, Fahrenkrug J (2008). Mice lacking the PACAP type I receptor have impaired photic entrainment and negative masking. Am J Physiol Regul Integr Comp Physiol 295: R2050R2058.
  • Hannibal J, Hsiung HM, Fahrenkrug J (2011). Temporal phasing of locomotor activity, heart rate rhythmicity, and core body temperature is disrupted in VIP receptor 2-deficient mice. Am J Physiol Regul Integr Comp Physiol 300: R519R530.
  • Harmar AJ, Marston HM, Shen S, Spratt C, West KM, Sheward WJ et al. (2002). The VPAC2 receptor is essential for circadian function in the mouse suprachiasmatic nuclei. Cell 109: 497508.
  • Harmar AJ, Sheward WJ, Morrison CF, Waser B, Gugger M, Reubi JC (2004). Distribution of the VPAC2 receptor in peripheral tissues of the mouse. Endocrinology 145: 12031210.
  • Hashimoto H, Nogi H, Mori K, Ohishi H, Shigemoto R, Yamamoto K et al. (1996). Distribution of the mRNA for a pituitary adenylate cyclase-activating polypeptide receptor in the rat brain: an in situ hybridization study. J Comp Neurol 371: 567577.
  • Hawke Z, Ivanov TR, Bechtold DA, Dhillon H, Lowell BB, Luckman SM (2009). PACAP neurons in the hypothalamic ventromedial nucleus are targets of central leptin signaling. J Neurosci 29: 1482814835.
  • Hughes AT, Fahey B, Cutler DJ, Coogan AN, Piggins HD (2004). Aberrant gating of photic input to the suprachiasmatic circadian pacemaker of mice lacking the VPAC2 receptor. J Neurosci 24: 35223526.
  • Ichikawa S, Sreedharan SP, Owen RL, Goetzl EJ (1995). Immunochemical localization of type I VIP receptor and NK-1-type substance P receptor in rat lung. Am J Physiol 268: L584L588.
  • Inagaki N, Yoshida H, Mizuta M, Mizuno N, Fujii Y, Gonoi T et al. (1994). Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells. Proc Natl Acad Sci U S A 91: 26792683.
  • Ishihara T, Shigemoto R, Mori K, Takahashi K, Nagata S (1992). Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 8: 811819.
  • Itoh N, Obata K, Yanaihara N, Okamoto H (1983). Human preprovasoactive intestinal polypeptide contains a novel PHI-27-like peptide, PHM-27. Nature 304: 547549.
  • Jamen F, Persson K, Bertrand G, Rodriguez-Henche N, Puech R, Bockaert J et al. (2000). PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. J Clin Invest 105: 13071315.
  • Jongsma H, Danielsen N, Sundler F, Kanje M (2000). Alteration of PACAP distribution and PACAP receptor binding in the rat sensory nervous system following sciatic nerve transection. Brain Res 853: 186196.
  • Jongsma H, Pettersson LM, Zhang Y, Reimer MK, Kanje M, Waldenstrom A et al. (2001). Markedly reduced chronic nociceptive response in mice lacking the PAC1 receptor. Neuroreport 12: 22152219.
  • Journot L, Waeber C, Pantaloni C, Holsboer F, Seeburg PH, Bockaert J et al. (1995). Differential signal transduction by six splice variants of the pituitary adenylate cyclase-activating peptide (PACAP) receptor. Biochem Soc Trans 23: 133137.
  • Juarranz MG, Santiago B, Torroba M, Gutierrez-Canas I, Palao G, Galindo M et al. (2004). Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. Rheumatology (Oxford) 43: 416422.
  • Kaltreider HB, Ichikawa S, Byrd PK, Ingram DA, Kishiyama JL, Sreedharan SP et al. (1997). Upregulation of neuropeptides and neuropeptide receptors in a murine model of immune inflammation in lung parenchyma. Am J Respir Cell Mol Biol 16: 133144.
  • Kawaguchi C, Tanaka K, Isojima Y, Shintani N, Hashimoto H, Baba A et al. (2003). Changes in light-induced phase shift of circadian rhythm in mice lacking PACAP. Biochem Biophys Res Commun 310: 169175.
  • Kawai K, Yokota C, Ohashi S, Isobe K, Suzuki S, Nakai T et al. (1994). Pituitary adenylate cyclase-activating polypeptide: effects on pancreatic-adrenal hormone secretion and glucose-lipid metabolism in normal conscious dogs. Metabolism 43: 739744.
  • Kienlen Campard P, Crochemore C, Rene F, Monnier D, Koch B, Loeffler JP (1997). PACAP type I receptor activation promotes cerebellar neuron survival through the cAMP/PKA signaling pathway. DNA Cell Biol 16: 323333.
  • Krempels K, Usdin TB, Harta G, Mezey E (1995). PACAP acts through VIP type 2 receptors in the rat testis. Neuropeptides 29: 315320.
  • Kumar S, Pioszak A, Zhang C, Swaminathan K, Xu HE (2011). Crystal structure of the PAC1R extracellular domain unifies a consensus fold for hormone recognition by class B G-protein coupled receptors. PLoS ONE 6: e19682.
  • Laburthe M, Couvineau A (2002). Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP. Regul Pept 108: 165173.
  • Laburthe M, Amiranoff B, Boige N, Rouyer-Fessard C, Tatemoto K, Moroder L (1983). Interaction of GRF with VIP receptors and stimulation of adenylate cyclase in rat and human intestinal epithelial membranes. Comparison with PHI and secretin. FEBS Lett 159: 8992.
  • Laburthe M, Couvineau A, Tan V (2007). Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides 28: 16311639.
  • Lamouche S, Martineau D, Yamaguchi N (1999). Modulation of adrenal catecholamine release by PACAP in vivo. Am J Physiol 276: R162R170.
  • Lee HW, Hahm SH, Hsu CM, Eiden LE (1999). Pituitary adenylate cyclase-activating polypeptide regulation of vasoactive intestinal polypeptide transcription requires Ca2+ influx and activation of the serine/threonine phosphatase calcineurin. J Neurochem 73: 17691772.
  • Lelievre V, Favrais G, Abad C, Adle-Biassette H, Lu Y, Germano PM et al. (2007). Gastrointestinal dysfunction in mice with a targeted mutation in the gene encoding vasoactive intestinal polypeptide: a model for the study of intestinal ileus and Hirschsprung's disease. Peptides 28: 16881699.
  • Levinson DF, Duan J, Oh S, Wang K, Sanders AR, Shi J et al. (2011). Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. Am J Psychiatry 168: 302316.
  • Luis J, Said SI (1990). Characterization of VIP- and helodermin-preferring receptors on human small cell lung carcinoma cell lines. Peptides 11: 12391244.
  • Lutz EM, Sheward WJ, West KM, Morrow JA, Fink G, Harmar AJ (1993). The VIP2 receptor: molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett 334: 38.
  • Mabuchi T, Shintani N, Matsumura S, Okuda-Ashitaka E, Hashimoto H, Muratani T et al. (2004). Pituitary adenylate cyclase-activating polypeptide is required for the development of spinal sensitization and induction of neuropathic pain. J Neurosci 24: 72837291.
  • Malhotra RK, Wakade TD, Wakade AR (1988). Vasoactive intestinal polypeptide and muscarine mobilize intracellular Ca2+ through breakdown of phosphoinositides to induce catecholamine secretion. Role of IP3 in exocytosis. J Biol Chem 263: 21232126.
  • Martin JL, Dietl MM, Hof PR, Palacios JM, Magistretti PJ (1987). Autoradiographic mapping of [mono[125I]iodo-Tyr10, MetO17]vasoactive intestinal peptide binding sites in the rat brain. Neuroscience 23: 539565.
  • Martinez C, Abad C, Delgado M, Arranz A, Juarranz MG, Rodriguez-Henche N et al. (2002). Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. Proc Natl Acad Sci U S A 99: 10531058.
  • Matsuyama S, Matsumoto A, Hashimoto H, Shintani N, Baba A (2003). Impaired long-term potentiation in vivo in the dentate gyrus of pituitary adenylate cyclase-activating polypeptide (PACAP) or PACAP type 1 receptor-mutant mice. Neuroreport 14: 20952098.
  • Miampamba M, Germano PM, Arli S, Wong HH, Scott D, Tache Y et al. (2002). Expression of pituitary adenylate cyclase-activating polypeptide and PACAP type 1 receptor in the rat gastric and colonic myenteric neurons. Regul Pept 105: 145154.
  • Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L et al. (1989). Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164: 567574.
  • Miyata A, Jiang L, Dahl RD, Kitada C, Kubo K, Fujino M et al. (1990). Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun 170: 643648.
  • Modlin IM, Bloom SR, Mitchell S (1978). VIP: the cause of the watery diarrhoea syndrome. Adv Exp Med Biol 106: 195201.
  • Moller K, Sundler F (1996). Expression of pituitary adenylate cyclase activating peptide (PACAP) and PACAP type I receptors in the rat adrenal medulla. Regul Pept 63: 129139.
  • Moreno D, Gourlet P, De Neef P, Cnudde J, Waelbroeck M, Robberecht P (2000). Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC2 receptor. Peptides 21: 15431549.
  • Moro O, Lerner EA (1997). Maxadilan, the vasodilator from sand flies, is a specific pituitary adenylate cyclase activating peptide type I receptor agonist. J Biol Chem 272: 966970.
  • Mounien L, Do Rego JC, Bizet P, Boutelet I, Gourcerol G, Fournier A et al. (2009). Pituitary adenylate cyclase-activating polypeptide inhibits food intake in mice through activation of the hypothalamic melanocortin system. Neuropsychopharmacology 34: 424435.
  • Neri G, Andreis PG, Prayer-Galetti T, Rossi GP, Malendowicz LK, Nussdorfer GG (1996). Pituitary adenylate-cyclase activating peptide enhances aldosterone secretion of human adrenal gland: evidence for an indirect mechanism, probably involving the local release of catecholamines. J Clin Endocrinol Metab 81: 169173.
  • Neumann JM, Couvineau A, Murail S, Lacapere JJ, Jamin N, Laburthe M (2008). Class-B GPCR activation: is ligand helix-capping the key? Trends Biochem Sci 33: 314319.
  • Nicole P, Lins L, Rouyer-Fessard C, Drouot C, Fulcrand P, Thomas A et al. (2000). Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist. Alanine scanning and molecular modeling of the peptide. J Biol Chem 275: 2400324012.
  • Ohtaki H, Nakamachi T, Dohi K, Aizawa Y, Takaki A, Hodoyama K et al. (2006). Pituitary adenylate cyclase-activating polypeptide (PACAP) decreases ischemic neuronal cell death in association with IL-6. Proc Natl Acad Sci U S A 103: 74887493.
  • Ottaway CA (1987). Selective effects of vasoactive intestinal peptide on the mitogenic response of murine T cells. Immunology 62: 291297.
  • Otto C, Kovalchuk Y, Wolfer DP, Gass P, Martin M, Zuschratter W et al. (2001a). Impairment of mossy fiber long-term potentiation and associative learning in pituitary adenylate cyclase activating polypeptide type I receptor-deficient mice. J Neurosci 21: 55205527.
  • Otto C, Martin M, Wolfer DP, Lipp HP, Maldonado R, Schutz G (2001b). Altered emotional behavior in PACAP-type-I-receptor-deficient mice. Brain Res Mol Brain Res 92: 7884.
  • Otto C, Hein L, Brede M, Jahns R, Engelhardt S, Grone HJ et al. (2004). Pulmonary hypertension and right heart failure in pituitary adenylate cyclase-activating polypeptide type I receptor-deficient mice. Circulation 110: 32453251.
  • Pantaloni C, Brabet P, Bilanges B, Dumuis A, Houssami S, Spengler D et al. (1996). Alternative splicing in the N-terminal extracellular domain of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor modulates receptor selectivity and relative potencies of PACAP-27 and PACAP-38 in phospholipase C activation. J Biol Chem 271: 2214622151.
  • Persson K, Ahren B (2002). The neuropeptide PACAP contributes to the glucagon response to insulin-induced hypoglycaemia in mice. Acta Physiol Scand 175: 2528.
  • Piggins HD (2011). Schizophrenia: zooming in on a gene. Nature 471: 455456.
  • Pisegna JR, Wank SA (1993). Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor. Proc Natl Acad Sci U S A 90: 63456349.
  • Pisegna JR, Wank SA (1996). Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor. Evidence for dual coupling to adenylate cyclase and phospholipase C. J Biol Chem 271: 1726717274.
  • Przywara DA, Guo X, Angelilli ML, Wakade TD, Wakade AR (1996). A non-cholinergic transmitter, pituitary adenylate cyclase-activating polypeptide, utilizes a novel mechanism to evoke catecholamine secretion in rat adrenal chromaffin cells. J Biol Chem 271: 1054510550.
  • Rangon CM, Goursaud S, Medja F, Lelievre V, Mounien L, Husson I et al. (2005). VPAC2 receptors mediate vasoactive intestinal peptide-induced neuroprotection against neonatal excitotoxic brain lesions in mice. J Pharmacol Exp Ther 314: 745752.
  • Raufman JP, Malhotra R, Singh L (1991). PACAP-38, a novel peptide from ovine hypothalamus, is a potent modulator of amylase release from dispersed acini from rat pancreas. Regul Pept 36: 121129.
  • Reichlin S (1988). Neuroendocrine significance of vasoactive intestinal polypeptide. Ann N Y Acad Sci 527: 431449.
  • Ressler KJ, Mercer KB, Bradley B, Jovanovic T, Mahan A, Kerley K et al. (2011). Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature 470: 492497.
  • Reubi JC (2000). In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Ann N Y Acad Sci 921: 125.
  • Reubi JC, Laderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA (2000). Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res 60: 31053112.
  • Reubi JC, Korner M, Waser B, Mazzucchelli L, Guillou L (2004). High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur J Nucl Med Mol Imaging 31: 803810.
  • Robberecht P, Waelbroeck M, De Neef P, Tastenoy M, Gourlet P, Cogniaux J et al. (1988). A new type of functional VIP receptor has an affinity for helodermin in human SUP-T1 lymphoblasts. FEBS Lett 228: 351355.
  • Robberecht P, Woussen-Colle MC, De Neef P, Gourlet P, Buscail L, Vandermeers A et al. (1991). The two forms of the pituitary adenylate cyclase activating polypeptide (PACAP (1-27) and PACAP (1-38)) interact with distinct receptors on rat pancreatic AR 4-2J cell membranes. FEBS Lett 286: 133136.
  • Robberecht P, Vertongen P, Velkeniers B, de Neef P, Vergani P, Raftopoulos C et al. (1993). Receptors for pituitary adenylate cyclase activating peptides in human pituitary adenomas. J Clin Endocrinol Metab 77: 12351239.
  • Robberecht P, Woussen-Colle MC, Vertongen P, De Neef P, Hou X, Salmon I et al. (1994). Expression of pituitary adenylate cyclase activating polypeptide (PACAP) receptors in human glial cell tumors. Peptides 15: 661665.
  • Said SI (1991). Vasoactive intestinal polypeptide: biologic role in health and disease. Trends Endocrinol Metab 2: 107112.
  • Said SI (1996). Vasoactive intestinal peptide and nitric oxide: divergent roles in relation to tissue injury. Ann N Y Acad Sci 805: 379387; discussion 387–378.
  • Said SI, Mutt V (1970). Polypeptide with broad biological activity: isolation from small intestine. Science 169: 12171218.
  • Said SI, Mutt V (1972). Isolation from porcine-intestinal wall of a vasoactive octacosapeptide related to secretin and to glucagon. Eur J Biochem 28: 199204.
  • Said SI, Rattan S (2004). The multiple mediators of neurogenic smooth muscle relaxation. Trends Endocrinol Metab 15: 189191.
  • Sharman JL, Mpamhanga CP, Spedding M, Germain P, Staels B, Dacquet C et al. (2011). IUPHAR-DB: new receptors and tools for easy searching and visualization of pharmacological data. Nucleic Acids Res 39: D534D538.
  • Sheward WJ, Lutz EM, Harmar AJ (1995). The distribution of vasoactive intestinal peptide2 receptor messenger RNA in the rat brain and pituitary gland as assessed by in situ hybridization. Neuroscience 67: 409418.
  • Sheward WJ, Lutz EM, Copp AJ, Harmar AJ (1998). Expression of PACAP, and PACAP type 1 (PAC1) receptor mRNA during development of the mouse embryo. Brain Res Dev Brain Res 109: 245253.
  • Shioda S, Shuto Y, Somogyvari-Vigh A, Legradi G, Onda H, Coy DH et al. (1997). Localization and gene expression of the receptor for pituitary adenylate cyclase-activating polypeptide in the rat brain. Neurosci Res 28: 345354.
  • Shioda S, Shimoda Y, Hori T, Mizushima H, Ajiri T, Funahashi H et al. (2000). Localization of the pituitary adenylate cyclase-activating polypeptide receptor and its mRNA in the rat adrenal medulla. Neurosci Lett 295: 8184.
  • Shivers BD, Gorcs TJ, Gottschall PE, Arimura A (1991). Two high affinity binding sites for pituitary adenylate cyclase-activating polypeptide have different tissue distributions. Endocrinology 128: 30553065.
  • Sorg O, Magistretti PJ (1992). Vasoactive intestinal peptide and noradrenaline exert long-term control on glycogen levels in astrocytes: blockade by protein synthesis inhibition. J Neurosci 12: 49234931.
  • Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeburg PH et al. (1993). Differential signal transduction by five splice variants of the PACAP receptor. Nature 365: 170175.
  • Sreedharan SP, Huang JX, Cheung MC, Goetzl EJ (1995). Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene. Proc Natl Acad Sci U S A 92: 29392943.
  • Stroth N, Eiden LE (2010). Stress hormone synthesis in mouse hypothalamus and adrenal gland triggered by restraint is dependent on pituitary adenylate cyclase-activating polypeptide signaling. Neuroscience 165: 10251030.
  • Sun C, Song D, Davis-Taber RA, Barrett LW, Scott VE, Richardson PL et al. (2007). Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS. Proc Natl Acad Sci U S A 104: 78757880.
  • Szabadfi K, Atlasz T, Kiss P, Danyadi B, Tamas A, Helyes Z et al. (2012). Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) are more susceptible to retinal ischemic injury in vivo. Neurotox Res 21: 4148.
  • Tan YV, Couvineau A, Murail S, Ceraudo E, Neumann JM, Lacapere JJ et al. (2006). Peptide agonist docking in the N-terminal ectodomain of a class II G protein-coupled receptor, the VPAC1 receptor. Photoaffinity, NMR, and molecular modeling. J Biol Chem 281: 1279212798.
  • Tan YV, Abad C, Lopez R, Dong H, Liu S, Lee A et al. (2009). Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 106: 20122017.
  • Tatemoto K, Mutt V (1981). Isolation and characterization of the intestinal peptide porcine PHI (PHI-27), a new member of the glucagon – secretin family. Proc Natl Acad Sci U S A 78: 66036607.
  • Tatsuno I, Uchida D, Tanaka T, Saeki N, Hirai A, Saito Y et al. (2001). Maxadilan specifically interacts with PAC1 receptor, which is a dominant form of PACAP/VIP family receptors in cultured rat cortical neurons. Brain Res 889: 138148.
  • Tomimoto S, Hashimoto H, Shintani N, Yamamoto K, Kawabata Y, Hamagami K et al. (2004). Overexpression of pituitary adenylate cyclase-activating polypeptide in islets inhibits hyperinsulinemia and islet hyperplasia in agouti yellow mice. J Pharmacol Exp Ther 309: 796803.
  • Tse DL, Pang RT, Wong AO, Chan SM, Vaudry H, Chow BK (2002). Identification of a potential receptor for both peptide histidine isoleucine and peptide histidine valine. Endocrinology 143: 13271336.
  • Tsukiyama N, Saida Y, Kakuda M, Shintani N, Hayata A, Morita Y et al. (2011). PACAP centrally mediates emotional stress-induced corticosterone responses in mice. Stress 14: 368375.
  • Tsutsumi M, Claus TH, Liang Y, Li Y, Yang L, Zhu J et al. (2002). A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes. Diabetes 51: 14531460.
  • Uchida D, Tatsuno I, Tanaka T, Hirai A, Saito Y, Moro O et al. (1998). Maxadilan is a specific agonist and its deleted peptide (M65) is a specific antagonist for PACAP type 1 receptor. Ann N Y Acad Sci 865: 253258.
  • Usdin TB, Bonner TI, Mezey E (1994). Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135: 26622680.
  • Vacic V, McCarthy S, Malhotra D, Murray F, Chou HH, Peoples A et al. (2011). Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. Nature 471: 499503.
  • Van Rampelbergh J, Gourlet P, De Neef P, Robberecht P, Waelbroeck M (1996). Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states. Mol Pharmacol 50: 15961604.
  • Vaudry D, Gonzalez BJ, Basille M, Anouar Y, Fournier A, Vaudry H (1998). Pituitary adenylate cyclase-activating polypeptide stimulates both c-fos gene expression and cell survival in rat cerebellar granule neurons through activation of the protein kinase A pathway. Neuroscience 84: 801812.
  • Vaudry D, Gonzalez BJ, Basille M, Fournier A, Vaudry H (1999). Neurotrophic activity of pituitary adenylate cyclase-activating polypeptide on rat cerebellar cortex during development. Proc Natl Acad Sci U S A 96: 94159420.
  • Vaudry D, Gonzalez BJ, Basille M, Pamantung TF, Fontaine M, Fournier A et al. (2000). The neuroprotective effect of pituitary adenylate cyclase-activating polypeptide on cerebellar granule cells is mediated through inhibition of the CED3-related cysteine protease caspase-3/CPP32. Proc Natl Acad Sci U S A 97: 1339013395.
  • Vaudry D, Pamantung TF, Basille M, Rousselle C, Fournier A, Vaudry H et al. (2002a). PACAP protects cerebellar granule neurons against oxidative stress-induced apoptosis. Eur J Neurosci 15: 14511460.
  • Vaudry D, Rousselle C, Basille M, Falluel-Morel A, Pamantung TF, Fontaine M et al. (2002b). Pituitary adenylate cyclase-activating polypeptide protects rat cerebellar granule neurons against ethanol-induced apoptotic cell death. Proc Natl Acad Sci U S A 99: 63986403.
  • Vaudry D, Falluel-Morel A, Basille M, Pamantung TF, Fontaine M, Fournier A et al. (2003). Pituitary adenylate cyclase-activating polypeptide prevents C2-ceramide-induced apoptosis of cerebellar granule cells. J Neurosci Res 72: 303316.
  • Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O et al. (2009). Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 61: 283357.
  • Vertongen P, Devalck C, Sariban E, De Laet MH, Martelli H, Paraf F et al. (1996). Pituitary adenylate cyclase activating peptide and its receptors are expressed in human neuroblastomas. J Cell Physiol 167: 3646.
  • Vertongen P, Schiffmann SN, Gourlet P, Robberecht P (1997). Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain. Peptides 18: 15471554.
  • Villalba M, Bockaert J, Journot L (1997). Pituitary adenylate cyclase-activating polypeptide (PACAP-38) protects cerebellar granule neurons from apoptosis by activating the mitogen-activated protein kinase (MAP kinase) pathway. J Neurosci 17: 8390.
  • Voice JK, Dorsam G, Lee H, Kong Y, Goetzl EJ (2001). Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor. FASEB J 15: 24892496.
  • Voice JK, Dorsam G, Chan RC, Grinninger C, Kong Y, Goetzl EJ (2002). Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide. Regul Pept 109: 199208.
  • Voice JK, Grinninger C, Kong Y, Bangale Y, Paul S, Goetzl EJ (2003). Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J Immunol 170: 308314.
  • Waschek JA, Casillas RA, Nguyen TB, DiCicco-Bloom EM, Carpenter EM, Rodriguez WI (1998). Neural tube expression of pituitary adenylate cyclase-activating peptide (PACAP) and receptor: potential role in patterning and neurogenesis. Proc Natl Acad Sci U S A 95: 96029607.
  • Watanabe T, Masuo Y, Matsumoto H, Suzuki N, Ohtaki T, Masuda Y et al. (1992). Pituitary adenylate cyclase activating polypeptide provokes cultured rat chromaffin cells to secrete adrenaline. Biochem Biophys Res Commun 182: 403411.
  • Wei Y, Mojsov S (1996). Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology. J Neuroendocrinol 8: 811817.
  • Xia M, Sreedharan SP, Bolin DR, Gaufo GO, Goetzl EJ (1997). Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. J Pharmacol Exp Ther 281: 629633.
  • Yada T, Sakurada M, Ihida K, Nakata M, Murata F, Arimura A et al. (1994). Pituitary adenylate cyclase activating polypeptide is an extraordinarily potent intra-pancreatic regulator of insulin secretion from islet beta-cells. J Biol Chem 269: 12901293.
  • Yamamoto K, Hashimoto H, Tomimoto S, Shintani N, Miyazaki J, Tashiro F et al. (2003). Overexpression of PACAP in transgenic mouse pancreatic β-cells enhances insulin secretion and ameliorates streptozotocin-induced diabetes. Diabetes 52: 11551162.
  • Yiangou Y, Di Marzo V, Spokes RA, Panico M, Morris HR, Bloom SR (1987). Isolation, characterization, and pharmacological actions of peptide histidine valine 42, a novel prepro-vasoactive intestinal peptide-derived peptide. J Biol Chem 262: 1401014013.
  • Yon L, Breault L, Contesse V, Bellancourt G, Delarue C, Fournier A et al. (1998). Localization, characterization, and second messenger coupling of pituitary adenylate cyclase-activating polypeptide receptors in the fetal human adrenal gland during the second trimester of gestation. J Clin Endocrinol Metab 83: 12991305.
  • Zaben M, Sheward WJ, Shtaya A, Abbosh C, Harmar AJ, Pringle AK et al. (2009). The neurotransmitter VIP expands the pool of symmetrically dividing postnatal dentate gyrus precursors via VPAC2 receptors or directs them toward a neuronal fate via VPAC1 receptors. Stem Cells 27: 25392551.
  • Zeng N, Athmann C, Kang T, Lyu RM, Walsh JH, Ohning GV et al. (1999). PACAP type I receptor activation regulates ECL cells and gastric acid secretion. J Clin Invest 104: 13831391.
  • Zhou CJ, Shioda S, Shibanuma M, Nakajo S, Funahashi H, Nakai Y et al. (1999). Pituitary adenylate cyclase-activating polypeptide receptors during development: expression in the rat embryo at primitive streak stage. Neuroscience 93: 375391.
  • Zupan V, Hill JM, Brenneman DE, Gozes I, Fridkin M, Robberecht P et al. (1998). Involvement of pituitary adenylate cyclase-activating polypeptide II vasoactive intestinal peptide 2 receptor in mouse neocortical astrocytogenesis. J Neurochem 70: 21652173.
  • Zusev M, Gozes I (2004). Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP. Regul Pept 123: 3341.